MDoutlook® is pleased to share excerpts from the most recent MDoutlook’s OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Acute Myeloid Leukemia (AML).
This research is the newest in a long line of impact studies following major data announcements in cancer. MDoutlook has covered the oncology space since 2008 in more depth and with more focus than most disease intelligence organizations.
This report is based on an on-line survey of US and European oncologists focused on AML.
Key Conclusions: Immediate Impact of New AML Data on Clinical Practice:
• Physicians believe midostaurin will have the greatest importance to their clinical practice with AML, and sorafenib and gilteritinib having slightly less clinical importance
• Midostaurin would be the dominant FLT3 inhibitor integrated into induction therapies for FLT3+ AML, while sorafenib is expected to be integrated into induction protocols as well
• For FLT3+ AML post-transplant maintenance therapy, midostaurin would be widely accepted, but sorafenib would be used by less than half of physician under these circumstances
Access the full complimentary AML OncoPoll report through the link. And contact us to discuss your oncology intelligence needs.
Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.
MDoutlook is growing and is looking for qualified Global Medical Analysts to join our enthusiastic team of disease experts. You can access the job posting here.
Direct your resume and cover letter to [email protected] (only candidates; no recruiters please).
We look forward to adding new stars to our team!
Recently announced advances in the treatment of Multiple Myeloma (MM), for both newly diagnosed and relapsed / refractory patients, have been quickly embraced by oncologists globally.
MDoutlook are pleased to share complimentary highlights from the most recent MDoutlook OncoPoll™: Clinical Impact of Recent Data Announcements in the treatment of Multiple Myeloma. This research is based on an on-line survey of US and European oncologists actively managing MM patients. Access the highlights here. Copies of the full report are available upon request.
If you have any questions or feedback, or want to discuss how MDoutlook can provide deep, customized insight to your specific oncology needs, please let us know.
Speak with the cancer and commercialization experts at MDoutlook about answering your critical questions that arise throughout the life cycle of your brand or service. Oncology is an increasingly complex area, because of the rapidly evolving multi-disciplinary approach to disease management and the intricate diagnosis and treatment of this disease.
Our team of MD and PhD medical analysts, MBA-level commercialization experts and support team of data and research analysts has delivered more than 450 cancer intelligence projects since 2008.
Powered by MDoutlook’s proprietary panel of 95,000 verified and profiled cancer treaters, MDoutlook will address your needs:
• Early: Disease Landscape, ThoughtLeader Identification
• Pre-Launch: Competitive Intelligence, Concept testing, Segmentation
• Launch: KPI Tracking, Adoption Drivers and Barriers, Targeting
• Maximization: KPI Tracking, Market Expansion, Competitive Intelligence
Review the latest fact sheet on our Oncology Life Cycle Intelligence capabilities here.
Contact us to discuss how MDoutlook can deliver on your oncology intelligence needs.
Since 2008, MDoutlook has built the largest panel of verified cancer treaters in the world. Now at over 95,000 members strong, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer.
MDoutlook offers clients a range of services powered by this proprietary oncology panel to address the needs of clinical, commercial and business development verticals at life science organizations.
Unlock this Total Oncology Intelligence to answer your questions.
Our team brings the experience of over 450 cancer intelligence projects to the bespoke and syndicated insight our clients require. Access the latest fact sheet on our Total Oncology Intelligence capabilities here.
Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.